X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Combogesic IV (acetaminophen & ibuprofen) is a opioid-free pain relief medicine. It is approved by USFDA for use in adults for relief of mild to moderate pain & the management of moderate to severe pain as an adjunct to opioid analgesics.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Combogesic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Dental and Oral Health Product Name: Tranexamic Acid Oral Rinse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
MCZ-DB (miconazole nitrate + domiphen bromide) vaginal cream is being evaluated in phase 2 clinical trials for the treatment of acute vulvovaginal candidiasis.
Lead Product(s): Miconazole Nitrate,Domiphen Bromide
Therapeutic Area: Infections and Infectious Diseases Product Name: MCZ-DB
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Purna Female Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).
Lead Product(s): PTX-252
Therapeutic Area: Oncology Product Name: PTX-252
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pleco Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
HY-029 (valaciclovir) is a viral dna polymerase inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of Herpes Simplex Infections.
Lead Product(s): Valacyclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: HY-029
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
FDA approved ANDA for Podofilox Gel, a tubulin binder causing cell mitotic arrest, making it ththe first generic topical drug product for the treatment of external genital and perianal warts.
Lead Product(s): Podophyllotoxin
Therapeutic Area: Infections and Infectious Diseases Product Name: Condylox-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Maxigesic via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Maxigesic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Product Name: Alenura
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vaneltix Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
The funding will be used for the first part of the development of HY-083, a TRPV1 agonist, administered intranasally as a spray, for the treatment of idiopathic rhinitis.
Lead Product(s): HY-083
Therapeutic Area: Immunology Product Name: HY-083
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Walloon Region
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 08, 2023
Details:
Maxigesic® via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Maxigesic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
